Labiotech.eu

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 9 Aug 2015

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections. The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and […]

August 9, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 7 Aug 2015

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

CureVac, a pioneer in the field of mRNA-based technology, today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac’s RNActive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to […]

August 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 6 Aug 2015

Aging-diseases expert Biophytis launches its IPO in Paris

[Update August 6th, 2015] A month after its Initial Public Offering in Paris, Biophytis just announced that the company raised an extra €6 million from a North-American investor. This fresh money is joining the €10 million successfully raised by the French biotech on July 8th, 2015. Original article published on June 26th, 2015: The Parisian biotech Biophytis […]

August 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Aug 2015

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for AbbVie, which is facing patent lost of its most profitable drug Humira. Mechelen, Belgium-based Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 6 Aug 2015

Here are 7 Biotech Stories you Must Read During the Holidays

The Holidays are a perfect time to enjoy the sun and relax peacefully on the beach but it’s also a great time to read inspiring stories about your favorite topic, Biotechs! For your delight, we bring you the most read biotech stories of this year. Discover or re-discover them and enjoy! January – The CRISPR’s Therapeutical revolution Six […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

The Most Advanced Bioplastic Plant to Be Built in France

Bio-on and Cristal Union will work together to build the most advanced plant producing bioplastics in France. This exclusive process will transform sugar beet co-products in a 100% biodegradable plastic! Your plastic bottle will soon be produced from sugar beet! Bio-on and Cristal Union just signed an agreement to work together on the construction of […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

Did Bavarian Nordic cheat on its clinical results?

The hedge fund Kerrisdale Capital just published a report explaining its position in Bavarian Nordic, showing that the Danish company’s lead candidate has ineffective results. Kerrisdale is inviting other investors to leave their shares in the company before it’s too late. Bavarian Nordic is under attack! Kerrisdale Capital, an hedge fund with track records in […]

August 5, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

Interview with Fabrice Plasson, Amoéba’s CEO: “We created a biocide using microorganisms”

Water treatment against pathogens has not changed since 1914 when we first discovered the use of chlorine. Industrial manufacturers are still using such chemicals to decontaminate waters involved in their process but can only destroy 0,5% of pathogens! The French company Amoéba, has discovered a way to eliminate 100% of pathogens without using any chemicals! […]

August 5, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 4 Aug 2015

A 100% Successful Ebola Vaccine Available in a Record Time

It’s a really good news in the fight against Ebola. A vaccine has shown 100% success to prevent the disease during the outbreak in Guinea! The vaccine, which has been tested in a record time, can be the key to end the west African epidemics. In an interim analysis published by The Lancet, the new vaccine has […]

August 4, 2015 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

Aging-diseases expert Biophytis launches its IPO in Paris

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Here are 7 Biotech Stories you Must Read During the Holidays

The Most Advanced Bioplastic Plant to Be Built in France

AstraZeneca Adds New Antisense Drugs to its Pipeline

Did Bavarian Nordic cheat on its clinical results?

Interview with Fabrice Plasson, Amoéba’s CEO: “We created a biocide using microorganisms”

A 100% Successful Ebola Vaccine Available in a Record Time

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!